Search
On December 25, 2025, Johnson & Johnson made an announcement stating that its groundbreaking therapeutic agent, Rycovne®—Amivantamab Injection (administered via subcutaneous injection), has received approval from the National Medical Products Administration. This approval is specifically for treating patients with advanced non-small cell lung cancer (NSCLC) who carry EGFR mutations. It's worth noting that an intravenous version of this drug had already been greenlit for the treatment of diverse types of EGFR-mutated NSCLC in the past. The newly sanctioned subcutaneous formulation, however, is a game-changer. It drastically cuts down the administration time to a mere 5 minutes or less and significantly cuts down on infusion-related reactions, offering patients a more convenient and safer treatment option.
-
C114 Communication Network -
Communication Home
